Trial Profile
An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs VLA 84 (Primary) ; Alum
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Sponsors Valneva
- 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
- 11 Apr 2016 Results published in the Vaccine
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.